# A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Source: https://onco.cc/trials/nct07169851/  
OnCo record `nct07169851` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of LY3537021 in advanced solid tumours, run by Eli Lilly and Company, now recruiting.

## Summary

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer is a phase 2 interventional study registered as NCT07169851 by Eli Lilly and Company, with 204 participants planned, started 2025-11-28 and due to reach its primary completion in 2026-12. Interventions recorded: LY3537021, Placebo, Standard of Care Antiemetic Therapies and Background Chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07169851
- Phase: 2
- Setting: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
- Sponsor: Eli Lilly and Company
- Enrolled: 204

## Sources

- ClinicalTrials.gov NCT07169851: https://clinicaltrials.gov/study/NCT07169851

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct07169851.json